Which of the following is a FDA-approved labeled indication for cyclobenzaprine hydrochloride?

A. Cough is typically managed with antitussive agents such as dextromethorphan or codeine, which suppress the medullary cough center. Cyclobenzaprine possesses no pharmacological activity against the tussive reflex. It is not indicated for respiratory or pulmonary symptoms. B. Hypertension requires antihypertensive classes such as ACE inhibitors, beta-blockers, or diuretics to reduce systemic vascular resistance. Cyclobenzaprine is a skeletal muscle relaxant and does not lower blood pressure. It is not an FDA-approved treatment for cardiovascular disorders. C. Muscle spasms associated with acute, painful musculoskeletal conditions are the primary FDA-approved indication for cyclobenzaprine. It functions centrally at the brainstem level to reduce tonic somatic motor activity. This action effectively alleviates localized skeletal muscle hyperactivity and pain. D. Inflammation is treated with nonsteroidal anti-inflammatory drugs or corticosteroids that inhibit the arachidonic acid cascade. Cyclobenzaprine lacks analgesic, antipyretic, or anti-inflammatory properties. It does not inhibit cyclooxygenase enzymes or modulate the immune response to tissue injury.